Gordon Naylor
Chief Financial Officer

UBS Healthcare Conference
17 June 2013
Agenda

- Foreign Exchange
- Debt Funding
- Segment Note
US Dollar Reporting Transition

CSL transitioned to US dollar reporting effective 1H2013

➢ Historical numbers provided Oct 2012

**Aim:**
- Reduce volatility in reported results
- Improve usability of IFRS accounts

**Outcome:**
- Significant reduction in FX impact on financial statements
- Timing of currency movements continues to impact
- Key currency pair is the US dollar to Swiss Franc
Key Currency Pair - USD:CHF

- Translation of profit for USD reporting
- Sale of product in USD
- Plasma flows

Reporting currency 2/3 of Group IG sales into the US

- A strengthening US dollar against the Swiss Franc produces a transaction FX tailwind & translation FX headwind
- Transaction FX substantially offsets translation FX
  - but not simultaneously
Improved Maturity Profile

Debt as at 30/06/12

Debt post US Private Placement
Segment Restructure

CSL completes Company reorganisation Feb 2013
- Historical recut of segment numbers to be provided Jun 2013
- New segment numbers for year ended 30 June 2012 and half year ended 31 December 2012

- Unaudited but will be subject to ‘Agreed Upon Procedures’ carried out by Company Auditors
- Assists investors during transition to new segment reporting
Reorganisation Rationale

Australian operations reorganised (as previously advised)

**CSL Behring**
- Australian plasma operations (Broadmeadows) integrated into the operations of CSL Behring
- Creates a single plasma business within the CSL Group
- Builds on scale and efficiencies achieved to-date
- Leverages new biotech and plasma manufacturing facilities currently under construction at Broadmeadows

**bioCSL**
- Creates a stand alone business unit within CSL group
- Incorporates vaccines, pharmaceutical and diagnostics
Segment Descriptions

Segment descriptions -

**CSL Behring**
- Manufactures, markets and develops plasma products

**bioCSL**
- Manufactures and distributes biotherapeutic products

**CSL Intellectual Property**
- Revenue and expenses from the licensing of IP
- Research & Development expenses on projects where commercialisation strategy has yet to be determined
Other movements include:
- R&D infrastructure
- Corporate allocation
- Immunohaemotology